Income Statement Vector Science and Therapeutics Corp.

Stocks

Market Closed - Toronto S.E. Other stock markets 20:59:59 06/08/2026 BST			5-day change	1st Jan Change
1.600 ^CAD	-2.44%		+5.26%	+3,100.00%

07-28	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products	CI
07-24	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026	CI

659c1f39a251d54d0a20096.ViGufoHlEZH3Z2RalATWVGLx75nP5M1TH2TnEMWstlA.OBadOMSfS_zEEiUi8mbkMFS5rtKnpvRlUAWXILPl2TxiEc8P7od0wrUpBw

Published financial data: VECTOR SCIENCE AND THERAPEUTICS CORP.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: August	2024	2025
Cost of Goods Sold, Total	-	150K
Gross Profit	-	-150K
Selling General & Admin Expenses, Total	-	307K
Other Operating Expenses, Total	-	307K
Operating Income	-	-457K
Currency Exchange Gains (Loss)	-	-14.75K
Other Non Operating Income (Expenses)	-	-426K
EBT, Excl. Unusual Items	-	-898K
EBT, Incl. Unusual Items	-	-898K
Earnings From Continuing Operations	-	-898K
Net Income to Company	-	-898K
Net Income - (IS)	-	-898K
Net Income to Common Incl Extra Items	-	-898K
Net Income to Common Excl. Extra Items	-	-898K
Per Share Items
Net EPS - Basic	-	-0.13
Basic EPS - Continuing Operations	-	-0.13
Basic Weighted Average Shares Outstanding	-	6.95M
Net EPS - Diluted	-	-0.13
Diluted EPS - Continuing Operations	-	-0.13
Diluted Weighted Average Shares Outstanding	-	6.95M
Normalized Basic EPS	-	-0.08
Normalized Diluted EPS	-	-0.08
Supplemental Items
EBITA	-	-457K
EBIT	-	-457K
Normalized Net Income	-	-561K
Supplemental Operating Expense Items
Marketing Expenses	-	11.64K
Selling and Marketing Expenses	-	11.64K
General and Administrative Expenses	-	295K
Research And Development Expense From Footnotes	-	150K

Fiscal Period: August	2024	2025
Assets
Cash And Equivalents	-	2.88M
Total Cash And Short Term Investments	-	2.88M
Other Receivables	600	-
Total Receivables	600	-
Prepaid Expenses	-	100K
Total Current Assets	600	2.98M
Other Intangibles, Total	-	23.48K
Total Assets	600	3.01M
Liabilities
Accounts Payable, Total	-	230K
Other Current Liabilities	-	22.72K
Total Current Liabilities	-	252K
Other Non Current Liabilities	-	1.03M
Total Liabilities	-	1.28M
Common Stock, Total	600	2.51M
Retained Earnings	-	-898K
Comprehensive Income and Other	-	115K
Total Common Equity	600	1.72M
Total Equity	600	1.72M
Total Liabilities And Equity	600	3.01M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	-	6.95M
ECS Total Common Shares Outstanding	-	6.95M
Book Value / Share	-	0.25
Tangible Book Value	600	1.7M
Tangible Book Value Per Share	-	0.24
Total Debt	0	0
Net Debt	-	-2.88M
Account Code - Inventory Valuation	-	3

Fiscal Period: August	2024	2025
Net Income	-	-898K
Other Operating Activities, Total	-	-27.95K
Change In Accounts Payable	-	252K
Change in Other Net Operating Assets	-	-100K
Cash from Operations	-	-774K
Sale (Purchase) of Intangible assets	-	-23.47K
Cash from Investing	-	-23.47K
Issuance of Common Stock	800	3.96M
Other Financing Activities, Total	-800	-277K
Cash from Financing	0	3.68M
Net Change in Cash	-	2.88M

Fiscal Period: August	2024	2025
Profitability
Return on Assets	-	-19.01
Return on Total Capital	-	-33.12
Return On Equity %	-	-104.1
Return on Common Equity	-	-104.1
Short Term Liquidity
Current Ratio	-	11.81
Quick Ratio	-	11.41
Operating Cash Flow to Current Liabilities	-	-3.07
Long Term Solvency
Total Liabilities / Total Assets	-	42.61
Growth Over Prior Year
Total Assets, 1 Yr. Growth %	-	501K
Tangible Book Value, 1 Yr. Growth %	-	283K
Common Equity, 1 Yr. Growth %	-	287K